Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Phillips-Medisize said today it bought drug-delivery device focused device strategy, product design and development service group Medicom Innovation Partner for an undisclosed amount. Read more
EnteroMedics said today that its Maestro device was used a pair of patients whose gastric sleeve procedures failed to bring the hoped-for weight loss and reduction in diabetes symptoms.
St. Paul, Minn.-based EnteroMedics calls the Maestro therapy “vBloc,” as it’s designed to stimulate the vagus nerve to control feelings of hunger and satiety. Read more
Tissuemed said it won approval from China’s FDA for its TissuePatch surgical sealant, claiming it as the 1st and only synthetic sealant approved in the People’s Republic.
Leeds, England-based Tissuemed said the approval, which followed a 2½-year process, covers all surgical applications for the TissuePatch sealant film, beyond its usual uses in neurological and thoracic surgeries. Read more
Titan Medical said today that it raised $16 million in a private placement with Chinese private equity player Shanghai Jugu Equity Investment Fund.
Shanghai Jugu paid about $56.9¢ apiece (C74.6¢) for some 27.9 million TMD shares, the Toronto-based robot-assisted surgery company said. Read more
Medtronic is shuffling the deck at its restorative therapies group as it looks to boost its ailing spine and neuromodulation businesses.
Fridley, Minn.-based Medtronic said yesterday that restorative therapies sales were up just 1% to $1.88 billion, including a -1% decline for its spine division at $737 million and a -5% slide to $494 million in neuromodulation. Read more